Safety, Biocompatibility, and Long-Term
Sustainability of Nanoparticle-Based Therapeutics: Current Insights and Future
Implications
Praveen J R1*, Dr.
Prafulla Prakash Adkar Patil2
1 Research Scholar,
Sunrise University,
Alwar, Rajasthan, India
praveenjavalisgk
2 Professor, Department of Pharmaceutical
Sciences, Sunrise University, Alwar,
Rajasthan, India
Abstract: Therapeutics derived from nanoparticles provide significant benefits to modern medicine, with the potential to deliver targeted medications, enhance the absorption of drugs by the body, and increase the effectiveness of therapies. The rapid growth of applications for nanomedicine in numerous domains like cancer treatment (oncology), treating heart diseases (cardiovascular), and developing vaccines (vaccine development) necessitates an evaluation of the safety, compatibility, and long-term viability of these products. Therefore, this research focuses on the current state of research in nanoparticle toxicity, their biological effects, and the potential environmental impact of their use through a qualitative and quantitative analysis of peer-reviewed literature (open-access journal articles), scientific articles, and international health publications.
Nano-particle therapy can play an important role in precision medicine; specifically, by providing targeted drug delivery and controlled release of medication into the body. However, the types of toxicological effects caused by the use of nano-particles (i.e. oxidative stress, immune response, accumulation in organs) are not completely understood, nor is there a complete understanding of how biocompatibility is influenced by nano-particle properties (i.e. physico-chemical properties such as size, surface charge, material composition). In addition, the translation of nano-particles into clinical practice faces challenges with regards to reproducibility, scalability and inconsistency in regulatory approval. There are also new environmental concerns associated with nano-particles; specifically, persistence in the environment, Ecotoxicity and sustainability. Green synthesis methods for producing nano-particles as well as lifecycle evaluations of nano-particle applications need to be considered when determining the overall effect of nano-particles on the environment.
Nanoparticle based therapeutics may have a transformative role in medicine but have major unresolved safety issues and sustainability challenges that require caution in future advances. Standardized regulatory frameworks, long-term toxicity studies, and interdisciplinary collaborations and the incorporation of environmental considerations will be important to developing nanomedicine safely and sustainably.
Keywords: Nanoparticles, Biocompatibility, Toxicity, Sustainability, Nanomedicine
1.
INTRODUCTION
Nanotechnology forms a key scientific basis for developing innovative therapies today. Through nanotechnology, manufacturers can create 'nano' or nanostructured materials to allow researchers to develop devices for diagnosis, prevention of illness, and treatment of illness at the nanoscale. In general, nanometer-sized particles that usually fall within this category are treated as having a particle size of between 1-100 nm. At this relative size compared with other types of manufactured items, they possess certain distinct physical characteristics, such as optical or electronic, magnetic and other surface treatments that do not exist in large quantities. By having these unique properties at the nanoscale, their properties, particularly the very high ratio of surface area to volume (i.e., their small individual size relative to their very large bulk size), their ability to chemically alter their surfaces to yield different physical characteristics and their closeness to biological targets make these nanoparticles highly effective for drug delivery and other purposes associated with disease treatment (Sim & Wong, 2021; Jia et al., 2023).
Therapeutic agents based on nanoparticles are drug formulations in which the agents either utilize nanoscale carriers or involve nanoscale materials. In nanomedicine, these systems are used to enhance the solubility of drugs, stabilize unstable compounds, modify their distribution in the body, control their release over time, and eliminate unwanted systemic toxicity. Nanomedicine has evolved from an initial focus on nanomaterial science and engineering research to developing more clinically relevant applications. A major milestone in the advancement of the field was the U.S. Food and Drug Administration's (FDA) approval of the first nanomedicine product, Doxil®, a liposomal formulation of doxorubicin, in July 1995 (Jia et al., 2023; Sim & Wong, 2021).
Nanomedicine has evolved over time to create many new classes of nanoparticles. Common types of nanoparticle that are widely studied today include polymeric, lipid-based, metallic, and inorganic nanoparticles. The polymeric nanoparticle class is the one that has been researched the most due to their ability to provide controlled release of drugs/therapeutic agents, high levels of stability, and ability to modify the surface functional groups. Lipid-based nanoparticles (e.g. liposomes, micelles and lipid nanoparticles) are essential for delivering drugs/therapeutic agents because they can encapsulate both hydrophilic drugs and hydrophobic drugs. Metallic nanoparticles (e.g. gold and iron oxide) are commonly researched for imaging, sensing and delivering drugs/therapeutic agents; inorganic nanoparticles (e.g. silica nanoparticles and quantum dots) are important for both imaging and for multiple-use applications in biomedicine (Patra et al., 2018; Sim & Wong, 2021).
The key scientific interest in these systems is their use in the targeted delivery of drugs and precision medicine. Nanoparticles can be customized to achieve improved tissue selectivity, increased circulation time, increased ability to cross biological barriers, and a much higher level of accumulation in diseased tissue than that which can be achieved with many conventional formulations. In addition, the ability to modify the surface of nanoparticles with ligands, polymers, or antibodies furthers the ability to support selective targeting, making nanoparticle systems an attractive option for the development of individualised and disease-specific treatment routines. The precision-oriented potential of these systems has made nanomedicine particularly important not only for oncology, but also for other complex diseases which are often poorly delivered through traditional means and have high levels of adverse effects (Thapa & Kim, 2023; Jia et al., 2023).
Nanoparticle based therapy has become an increasingly relevant area in healthcare due to the overwhelming number of new therapies (e.g., liposomal and polymeric systems, lipid nanoparticles, and nanocrystals) being developed from nanotechnology around the world. In addition to combining the use of available therapies into new therapeutic agents, more conventional and practical applications of nanotechnology are being developed through the use of nanoparticles to provide more efficient pharmacokinetic profiles of drug products, higher drug concentrations at the intended site(s) of action, and less non-specific toxicity associated with many conventional dosage forms. Most all of these products have received approval for clinical use as nanomedicines and have shown positive clinical results in all phases of clinical studies (Jia et al., 2023; Thapa & Kim, 2023).
Simultaneously, this research has a necessary link to the ongoing restrictions present in traditional drug delivery approaches. Some of these issues within traditional drug formulations include reduced solubility, poor stability, quick degradation, decreased bioavailability, multiple daily dosing needs, and a lack of targeted therapeutic distribution. These drawbacks contribute to the potential decrease in the efficacy level of a medication; conversely, pharmaceutical products with systematic side effects may increase the potential for harm to patients. Nanoparticle-based formulations have been suggested as a solution to address many of the challenges associated with traditional drug delivery systems because they may provide the ability to provide better control over the release of medications while offering protection to the therapeutics they carry as well as increasing their chances for uptake and providing a more localized means of delivering or targeting the medications being delivered. Nanoparticle-based formulations are particularly appealing for chronic illnesses requiring long-term management/treatment, as well as cancer, and other chronic diseases (Patra et al., 2018; Thapa & Kim, 2023).
Nanoparticles, while having valuable properties, do pose risks as well. There is a lot of information in the literature about the unaddressed concerns about potential toxicity, immunological reaction, how biodegradable they will be and persistence in the environment, and whether large amounts of nanoparticles will be present in the environment. Nanoparticles may interact with living cells, proteins, immune systems and organs in different ways with respect to their unique physical characteristics such as size shape charge coating composition and the method of introduction into the body. Scholars in the field of green nanomedicine have commented on the significant amount of growth in nanotechnology as compared to the lack of adequate attention given to potential longer-term health and environmental impact related to toxicity which makes complete and systematic reviews and thorough evaluations of these technologies absolutely necessary (Jahangirian et al., 2017; Patra et al., 2018).
Current advances in nanomedicine hint that this area is transitioning into a more translational and commercially prominent phase. Studies analyzing licensed nanomedicine indicate a wide variety of clinically proven drug formulations spread over several disease categories. Cancer treatment, infection control, and cardiovascular drugs are the dominant ones among them. On the other hand, many researchers doubted the success of nano-based treatment in clinical trials. There concerns were mainly connected with the toxicity and activation of the immune system, which in some cases brought to severe side-effects. But researchers envisage the field of clinical applications of nanoparticles as highly promising and exciting. In a recent international conversation, attention was paid to the still-present gap between nanotechnology research and clinical practice (Jia et al., 2023).
Due to growing demand for nanoscale medicine, more funding for research, approval from the FDA, and increased acceptance of therapies designed to target specific disease processes (e.g., targeted therapies), there has been a significant expansion of the nanomedicine industry. Current market analysis indicates that nanomedicine encompasses both experimental drug delivery systems and products that have already been approved and marketed by the FDA. However, these developments face ongoing challenges in translation aspects including reproducibility, adequate characterization, assay standardization, and thorough biological evaluation (Thapa & Kim, 2023).
Another major trend relates to the increasing linkage between nanoparticle therapeutics and precision medicine. Recent reviews characterize the use of nanomedicine as a means of delivering targeted therapy to specific patients since nanocarriers can be engineered to enhance biodistribution, minimize non-specific delivery, and facilitate disease-specific targeting. This inclination is a perfect match with the general medical movement focusing on tailored therapeutics instead of the one-size-fits-all treatment method (Sim & Wong, 2021; Thapa & Kim, 2023).
Another new revolution is the transition to green nanotechnology and the invention of biodegradable nanoparticles. Articles on green nanomedicine point out the necessity of safer synthesis methods, the use of renewable materials, reduction of hazardous wastes, and finding better degradation profiles. This environmentally friendly direction has been gaining importance since the future nanotherapeutics will be evaluated not only by effectiveness but also by their long-term biological and environmental compatibility (Jahangirian et al., 2017).
Despite making great strides in the field, the main research issue has not yet been solved: it is generally agreed that the safety, biocompatibility, and sustainability of nanoparticle-based therapeutics for a long period of time are still unknown. Reviews that are published regularly demonstrate that while data on short-term effectiveness have developed significantly, the knowledge of long-term toxicology has lagged. There are still uncertainties about unremitting exposure, buildup of nanoparticles in organs, biodegradation pattern, activation of immune system, and potential effects on the environment following production, use, and disposal (Patra et al., 2018; Thapa & Kim, 2023).
A lack of long-term toxicology data and a lack of standardization among regulatory authorities is another issue of concern. Multiple studies have noted that the methods used to characterize, to test biologically, and to assess the safety of the products of biotechnology, like those created through gene editing, remain insufficiently harmonized across the entire biotechnology sector. Such a situation significantly reduces study comparability, thereby hindering the timely and responsible clinical translation. Besides, the accumulation of NPs in the environment and the wider ecological impacts are still largely unknown, particularly with regard to sustainable production and lifecycle issues (Jahangirian et al., 2017; Thapa & Kim, 2023).
The objective of this paper was to thoroughly scrutinize the latest scientific publications on the safety and toxicity of therapeutics based on nanoparticles, especially the compatibility of such nanotherapeutics with biological systems and their long-term sustainability, among other aspects. This paper primarily focused on evaluating the interactions of various types of nanoparticles with cells and tissues as well as their elicitation of immune responses. Besides that, it explored issues of nanoparticle toxicity and whether insufficient biodegradability may result in the persistence of these particles in the organism and the environment.
This paper further aimed at finding out what are the main areas of nanomedicine research which if addressed, will allow for the safe and responsible use of nanoparticles in medicine. In addition, this paper sought to organize the main body of existing scientific knowledge in such a way as to inform and bolster research planning, design of stronger assessment methods, and the pursuit of therapeutic development that is more in line with the concept of sustainability. This paper involved qualitative, analytical, and review methods and relied entirely on secondary data. The data for the paper were made up of peer-reviewed articles from open-access scientific journals as well as official scientific and regulatory sources and other publicly available literature mainly accessed through platforms like PubMed, PubMed Central, and journal websites. The considered literature was mainly composed of nanoparticle toxicity and safety-focused publication and review papers along with articles related to approved nanomedicines, formulation issues, green nanotechnology, and sustainability concerns.
Within the last 10 to 15 years
studies were given the most priority to analyze the situation from the
perspectives of today. In addition, to establish how the concept has evolved
over time and to provide insight into its historical roots, there are a few of
the very earliest references from the field available within published
literature. A thematic content analysis was then performed from the collected
literature to detect and organize the presence of major themes (toxicity,
biocompatibility, targeting performance, translational barriers, regulation and
sustainability). The themes identified were then compared and synthesized to
identify areas of agreement and disagreement, as well as any knowledge gaps
that exist within the current literature. However, there were limitations that
existed in this analysis such as: the analysis utilized only published
materials, and the differences in experimental conditions, nanoparticle
characteristics, methodologies, and outcome measures between studies greatly
hindered the ability to make direct comparisons and draw meaningful conclusions
across all of the nanoparticle subclasses.
2. SAFETY
AND TOXICOLOGICAL ASSESSMENT OF NANOPARTICLE-BASED THERAPEUTICS
Mechanisms of Nanoparticle Toxicity
The way nanoparticles behave in both
the cellular and molecular environment will largely dictate how toxic
nanoparticle-based therapies can be. Depending upon their shape, size, surface
characteristics, and material, nanoparticles can enter cells through a number
of different mechanisms, such as passive diffusion, phagocytosis, and
endocytosis. Once inside the cell, a nanoparticle could interact with various
intracellular structures and lead to the dysfunction of cells (Patra et al.
2018) Toxicity due to the generation of reactive oxygen species is one of the
most significant routes by which nanoparticles are toxic. The generation of
high levels of reactive oxygen species can lead to cellular imbalances and
oxidative stress. Reactive oxygen species can damage lipids, proteins, and
nucleic acids, resulting in either DNA damage or programmed cell death. Research
indicates that the degree of toxicity of nanoparticles is primarily
dose-dependent; therefore, doses that are too high can be lethal; however,
lower doses may remain biocompatible (Khan et al., 2019).
Organ-Specific Toxicity and
Bioaccumulation
Nanoparticles tend to accumulate in
higher amounts than other types of isolated contaminants because they can
target organs involved with the filtration, detoxification, and systemic
circulation of blood. The organ with the greatest accumulation or concentration
of particles is the liver because of its reticuloendothelial system that serves
as an avenue for filtering particles out of blood. The kidneys may also have
high levels of nanoparticle accumulation that could lead to nephrotoxicity,
while inhaled nanoparticles may also accumulate in lung tissues and cause
respiratory disease through inflammation (De Jong & Borm, 2008). Also, some
nanoparticles can cross the blood-brain barrier, increasing concerns regarding
their potential impact on the brain. Prolonged exposure to nanoparticles may
result in bioaccumulation, potentially leading to prolonged toxicity. Studies
in laboratory animals have shown that implanted nanoparticles retain in tissues
cause damage to the organs over time; however, there are currently few reports
describing such effects in humans (Patra et al., 2018).
Immunogenic and Inflammatory
Responses
Nanoparticles can have a marked
effect on the immune system, potentially either stimulating or suppressing
immune responses. Upon entry into the body, nanoparticles may activate certain
immune cells, such as macrophages or dendritic cells, which can then stimulate
the production of inflammatory cytokines. The interaction of nanoparticles with
the immune system may lead to hypersensitivity or an inflammatory side effect
(Dobrovolskaia & McNeil, 2007). One of the best-known examples of this is
when nanoparticles activate the complement system, leading to rapid
hypersensitivity reactions that mimic allergic reactions (complement
activation-related pseudoallergy [CARPA]). Some liposomal and polymeric
nanocarriers have been associated with these types of reactions, particularly
for use in drug delivery (Dobrovolskaia & McNeil, 2007).
Influence of Physicochemical
Properties
Nanoparticles have specific
chemical/physical characteristics that will heavily shape their overall safety
profiles. For instance, attributes such as size, shape, surface charge, and
surface coatings can potentially impact the degree to which they can be taken
up by cells, distributed within the body, and exhibit toxic effects. In
general, smaller sized particles are capable of providing greater levels of
chemical reactivity and penetrating more deeply into cells, with potential for
greater levels of toxicity. Surface charge has an impact on how nanoparticles
will behave when they are in contact with biological membranes, while coatings
and other forms of surface modification primarily serve to improve stability of
the particles and reduce adverse interactions. Additionally, surface
modification methods (e.g., the addition of polyethylene glycol, PEG) are
commonly utilized to render nanoparticles more compatible with living systems
and less detectable by the immune system. Furthermore, the degree to which
nanoparticles remain stable and the manner in which they degrade in the body
will ultimately dictate how long they exist in the biological system and thus
influence their safety in the long-term.
Regulatory Toxicology Challenges
Even though many investigations have
been done into the effects of nanoparticles as medicinal products, evaluating
their safety for regulatory bodies remains extremely challenging. For instance,
a significant issue is that there are no commonly accepted testing
methodologies to evaluate nanoparticle toxicity. Research methods,
characterization of the particles and biological systems differ considerably
making it very difficult to compare results of the various studies done. In
addition, the regulations differ from one country/agency to another and as a
result, the evaluations of safety and how to approve a product differ across
all countries and regulatory authorities. Additionally, most of the current
legislation is for conventional drugs and does not take into account the unique
properties of nanoparticles; hence, there is an increasing need for risk
assessment systems that can be used internationally; these systems should used
provide a focus upon the safe use of nanomaterials along with other factors
such as potential long-term toxicity, environmental impacts, and material
lifecycle analysis (De Jong & Borm, 2008).
3.
BIOCOMPATIBILITY AND CLINICAL TRANSLATION OF NANOPARTICLES
Concept and Determinants of
Biocompatibility
In the biomedical arena,
biocompatibility is the property of a material (for example nanoparticles) to
carry out the desired function without causing detrimental biological
responses. The main features of nanoparticle-based therapeutics are non-toxic
effects, interaction with cells in a controllable manner, and a safe fit in the
biological system (Patra et al. 2018). Nanoparticles going inside the body meet
proteins, cells, and tissues. As a result, a complex and changing surface is
formed which decides the nanoparticles' biological destiny. Forming a protein
corona is one of the key events in these kinds of interactions, where one or
more layers of biomolecules get attached to the nanoparticle surface. Such a
corona changes the nanoparticle's 'identity' and determines its cellular
uptake, immune system recognition, and its distribution in the body (Monopoli
et al. 2012). The type of protein corona depends on the characteristics of
nanoparticles such as size, surface properties, and the interaction with the
surrounding biological environment. Thus, it stands out as one of the chief
factors in adjusting the biocompatibility of nanoparticles.
Evaluation Techniques for
Biocompatibility
Biocompatibility is assessed by
integrating in vitro, in vivo, and clinical studies. In vitro assays act as
initial screenings (also referred to as primary screening) for testing the
potential of nanoparticles by examining parameters such as cytotoxicity,
hemocompatibility and oxidative stress. These assays provide information on the
effect of nanoparticles on cell viability, membrane integrity, and blood
compatibility (Khan et al., 2019). In vivo assays are performed using animal
models to evaluate biodistribution; organ specific accumulation; immunological
response; and systemic toxicity. The results from these assays provide
necessary information to support the understanding of how nanoparticles behave
within live biological systems. Ultimately, the final step that serves as an
assessment of safety and efficacy of nanoparticle formulations in humans is
completed by conducting clinical trials. While the performance of in vitro and
animal research provides useful information that can be converted to clinical
applications, significant obstacles exist due to the high degree of biological
variability that exists among human subjects (Patra et al. 2018).
Biodegradability and Clearance
Mechanisms
The biodegradation and removal
characteristics of nanotubes are critical factors determining their long term
safety. Nanotubes are removed from the body primarily through the kidney or
liver depending on their size, chemical composition and surface properties.
Small nanotube particulates can pass through the glomerular barrier and be
eliminated from the body in urine. Conversely, large particulates are usually
taken up by the liver and eliminated by bile (Longmire et al. 2008).
Biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA) have been
widely utilized to produce non-toxic degradation products of nanotubes. Proper
balance must be maintained between accumulation and removal since an excess of
either will lead to chronic toxicity and/or organ dysfunction.
Clinical Applications and Safety
Profiles
Nanoparticle-based therapeutics have
shown a huge potential for treating a number of different clinical conditions.
For cancer treatment, nanoparticle drug delivery systems such as liposomes and
polymers are currently being used to administer chemotherapy drugs in a way
that is more targeted and less toxic to healthy cells. Other nanocarriers like
dendrimers are also being developed for targeted cancer therapy. Especially in
their cardiovascular and neurological applications, nanoparticles substantially
aid drug delivery by crossing difficult biological boundaries such as the
blood-brain barrier, thus significantly enhancing therapeutic outcomes (Patra
et al. 2018). In many cases, nanoparticle delivery systems have better safety
profiles than traditional treatment methods as the drug release can be finely
controlled with minimal side effects being experienced. Despite this, safety
results are primarily determined by the nature and makeup of nanoparticles.
Barriers to Clinical Translation
Though the results are promising,
there are some barriers that make it difficult for nanoparticle-based
therapeutics to actually get into use in clinics. One of the challenges is to
figure out how to produce these nanoparticles on a large (industrial) scale
while maintaining the same quality as in the lab. Since different methods may
give different results, it is difficult to reproduce (repeat) in some
instances. On top of that, there are concerns about ethics and safety, especially
when it comes to potential (long-term) toxicity and environmental impact.
Besides, it is a fact that the high cost of (research and development),
including research, testing, and regulatory approval, limits widespread
adoption. Such difficulties point to the importance of having (standardized)
protocols, manufacturing technologies that are better/improved and, regulatory
frameworks that are stronger to enable the translation of nanomedicine into
clinical practice (Khan et al., 2019).
4. LONG-TERM
SUSTAINABILITY AND ENVIRONMENTAL IMPLICATIONS
The
hazard of nanoparticles to many forms of aquatic organisms can be thought of as
being a significant issue for the ecosystem due to ecological toxicity. The
ecological toxicity that results from exposure to nanoparticles has the
potential to cause damage to many types of aquatic organisms including
bacteria; small aquatic vegetation; and higher level species such as fish and
invertebrate animals. The types of damage to these organisms include but are
not limited to oxidative damage, cellular damage, reductions in growth rate,
and alterations in reproductive behaviour. The microorganisms in the aquatic
food web are of particular concern, as they play a key role in nutrient
cycling, and exposure of microorganisms to nanoparticles may lead to
disruptions in microbial communities and potentially have ecological
consequences that would propagate through food webs from the bacterial level to
the highest trophic levels. One possible consequence of the bioaccumulation of nanoparticles
by organisms at lower levels of the aquatic food web, when those organisms are
consumed by organisms at higher levels of the aquatic food web, is that
nanoparticles may also be passed all the way through the entire food chain and
to the last animal that is consumed at the very top of the aquatic food web. At
this last level of the aquatic food web, organisms may be contaminated with
nanoparticles for a significant amount of time, and this could potentially
negatively impact the biodiversity of the aquatic ecosystem and the overall
health and functioning of the entire aquatic ecosystem. Biodiversity is
affected in a complicated way that depends on the level of nanoparticles
released, time of exposure, and the environmental conditions however studies
continue to show the possible risks of no-degradable nanoparticles to water and
land ecosystems as well.
Fundamentally,
developing sustainable nanotechnology is an important response to the issue of
environmental degradation, as it provides ways to decrease ecological harm.
Through Green synthesis methods, nanoparticles can be produced through
non-toxic substances and processes such as plant extracts, other biological
systems, and safe solvents as opposed to hazardous materials, thus reducing the
environmental impact of pollution and providing improved safety properties for
the nanoparticles themselves. In addition, there are further methods that
support the use of biodegradable and environmentally safe nanomaterials by
creating nanoparticles that will ultimately break down into non-toxic
byproducts following the delivery of their functions; thus, reducing the burden
on finite resources in nature and the accumulation of toxic products in the
environment. Furthermore, other strategies have been pursued to minimize the
production of harmful side-products from the synthesis of nanoparticles by
refining the performance of the methods used to create nanoparticles as well as
by implementing cleaner processing means of producing nanoparticles. Together,
all of these efforts will ultimately lead to a more sustainable and responsible
creation of nanomedicine.
The fast-paced growth in the area of
nanomaterials and their related technologies is creating considerable ethical
and policy challenges, which raise questions about their safe and responsible
use. Just as responsible innovation frameworks discuss the need for balance
among technological progress, sustainable environmental stewardship, and public
health safety; the demand for the creation of environmental regulations that
specifically address the unique properties and risks associated with
nanomaterials is increasing. Existing guidance documents are inadequate for
addressing the special properties and risks associated with nanomaterials, so
policymakers will need to establish long-term, systematic approaches for
evaluating environmental, health and safety impacts from the beginning stages
through the end of a product's life cycle (e.g. residuals of materials disposed
in landfills) and be prepared to manage any unanticipated/unpredictable impacts
on the environment, human population health, or safety. Further, as
nanomaterial properties evolve and become part of the everyday life through
interaction with humans, these nanoparticles may present long-term public
health risks. The three strategies to achieve socially and environmentally
responsible development of nanomaterials: full disclosure of nanomaterial
properties and uses to the public; engaging stakeholders (businesses and members
of the general population) in developing, implementing and evaluating
nanomaterial regulations; and establishing a framework for collaboration among
researchers from different disciplines.
5.
CONCLUSION AND RECOMMENDATIONS
This
report reviewed existing studies of nanomedicines in order to evaluate their
long-term safety, biocompatibility, and sustainability as therapeutic agents.
Results from this investigation indicated that nanoparticles may provide
significant therapeutic advances by improving the efficiency of drug delivery,
precision of targeting, and reducing systemic side effects compared to
conventional methods of treating disease. In addition, nanoparticles could
change the pharmacokinetics of drugs, increase the bioavailability of drugs,
and provide the opportunity for localized delivery of drugs, thereby
representing a significant departure from current methods of delivering
healthcare. Nevertheless, the study results indicated that safety and toxicity
issues are still not entirely addressed. Although short-term investigations
have shown good results, there is a lack of agreement on the long-term toxic
effects, particularly regarding chronic exposure, bioaccumulation, and toxicity
to specific organs. It has been demonstrated that the ways nanoparticles
interact with biological systems are not only very complicated but also depend
on several factors such as size, composition, and surface features.
Consequently, forecasting their long-term behavior in the human body is still a
major problem.
Moreover,
research has shown that biocompatibility changed quite a lot depending on the
kind of material and the design of the nanoparticle system. Some formulations
had achieved sufficiently compatibility with the body and very few side
effects, while others had triggered immune responses, inflammation, and even
cell death. The Omar family has been in the textile business for over 80 years
and owns the largest fine textile manufacturing company in North America, Omar
Hayek & Co., Inc. (Omar Hayek). Out of their desire to increase their
product lines, the Omar family founded Hayek Engineering, Inc., as a way to
provide the newly designed manufactured textiles (as well as other manufactured
products) to their customers.
The
Omar family has always been committed to innovation and quality in their work,
which began when they opened their first factory in Cairo. Their dream of
providing quality and comfort to their customers continues through Hayek
Engineering and the company's two state-of-the-art facilities: one in Chicago,
Illinois, and one in North Little Rock, Arkansas.
HAYEK
exists to manufacture products that enhance the lives of all people and to
create jobs within the community through job creation and business opportunity
creation to help sustain a healthy economy. By providing both employer and
employee with a safe environment in which to work, HAYEK can continue to
provide excellent service and innovative products to customers, while helping
develop new jobs in the community where they operate.
Recommendations
According to the research results, the authors have made a few significant suggestions for ensuring the safe and continued growth of nanoparticle-based medicines. First of all, nanomedicine-specific global regulatory frameworks development is highly needed. These frameworks should take into account the special characteristics of nanoparticles and lay down standardized guidelines for toxicity testing, risk assessment, and clinical evaluation. Besides, in-depth and long-term toxicity investigations as well as ongoing clinical follow-ups should become the main focus. It is necessary to shed light on the effects of continuous exposure, bioaccumulation behavior, and late-onset toxicity through future studies.
Long-term human studies would be the most trustworthy way to get a comprehensive understanding of the safety of nanoparticle-based therapies. Finally, it is necessary to step up the production of biodegradable and green nanoparticles. The scientific community and business circle should emphasize the use of nature-friendly materials and production methods that have less impact on the environment. Moreover, the creation of nanoparticles that can naturally break down into harmless compounds would go a long way in mitigating the risks linked to their accumulation in the environment.
Fourth,
facilitating interdisciplinary collaboration between scientific, clinical,
regulatory, and industrial stakeholders is essential. The complexities of
nanomedicine necessitate combined efforts from multiple disciplines: material
science, toxicology, pharmacology, environmental science, and public health.
By
employing an integrated collaborative approach that shares knowledge and
improves the overall quality of research, nanomedicine can more readily become
available for clinically safe and effective applications. Lastly,
sustainability evaluation ought to become a Throughout the entire lifecycle of
nanomedicines, from the sourcing of the raw materials to the disposal, the
environmental impacts should be deliberately factored in at the stage of the
product design and evaluation. Applying life cycle thinking and responsible
innovation methodologies will not only make the developments in nanotechnology
result in human health improvements but also in the conservation of the
environment for the future generations.
1.
De
Jong, W. H., & Borm, P. J. A. (2008). Drug delivery and nanoparticles:
Applications and hazards. International Journal of Nanomedicine, 3(2),
133–149. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2673638/
2.
Dobrovolskaia,
M. A., & McNeil, S. E. (2007). Immunological properties of engineered
nanomaterials. Nature Nanotechnology, 2(8), 469–478.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2570468/
3. Jahangirian, H., Lemraski, E. G., Webster, T. J., Rafiee-Moghaddam, R., & Abdollahi, Y. (2017). A review of drug delivery systems based on nanotechnology and green chemistry: Green nanomedicine. International Journal of Nanomedicine, 12, 2957–2978. https://www.dovepress.com/a-review-of-drug-delivery-systems-based-on-nanotechnology-and-green-ch-peer-reviewed-fulltext-article-IJN
4. Jia, Y., Jiang, Y., He, Y., Zhang, W., Zou, J., Magar, K. T., Boucetta, H., Teng, C., & He, W. (2023). Approved nanomedicine against diseases. Pharmaceutics, 15(3), 774. https://www.mdpi.com/1999-4923/15/3/774
5.
Khan,
I., Saeed, K., & Khan, I. (2019). Nanoparticles: Properties, applications
and toxicities. Arabian Journal of Chemistry, 12(7), 908–931. https://www.sciencedirect.com/science/article/pii/S1878535217300990
6.
Khan,
I., Saeed, K., & Khan, I. (2019). Nanoparticles: Properties, applications
and toxicities. Arabian Journal of Chemistry, 12(7), 908–931. https://www.sciencedirect.com/science/article/pii/S1878535217300990
7.
Longmire,
M., Choyke, P. L., & Kobayashi, H. (2008). Clearance properties of
nano-sized particles and molecules as imaging agents: Considerations and
caveats. Nanomedicine, 3(5), 703–717.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2775654/
8.
Monopoli,
M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012). Biomolecular coronas
provide the biological identity of nanosized materials. Nature
Nanotechnology, 7(12), 779–786.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534012/
9. Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. del P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., Habtemariam, S., & Shin, H.-S. (2018). Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology, 16(1), 71. https://link.springer.com/article/10.1186/s12951-018-0392-8
10. Sim, S., & Wong, N. K. (2021). Nanotechnology and its use in imaging and drug delivery (Review). Biomedical Reports, 14(5), 42. https://pmc.ncbi.nlm.nih.gov/articles/PMC7953199/
11. Thapa, R. K., & Kim, J. O. (2023). Nanomedicine-based commercial formulations: Current developments and future prospects. Journal of Pharmaceutical Investigation, 53(1), 19–33. https://pmc.ncbi.nlm.nih.gov/articles/PMC9761651/